Wednesday 11 March 2026

One To Watch

Pathios Therapeutics

A UK-based biotechnology company developing first-in-class therapies for cancer.

Company Overview

Want to Update your Company's Profile?


Latest Pathios Therapeutics News

Bristol Myers backs Pathios as part of $25 million Series B
19 April 2024
More Pathios Therapeutics news >


Today's issue

FDA nod for Wellcovorin in rare genetic disorder
Pharmaceutical
FDA nod for Wellcovorin in rare genetic disorder
10 March 2026
Biosimilars
Russia’s Biocad risks losing market for cancer drug pertuzumab due to Roche dispute
10 March 2026
Biotechnology
The milestones keep coming as Dewpoint approaches ‘inflection point’
10 March 2026
Biotechnology
BioNTech falls on 2025 results and founders’ moves
10 March 2026
Biosimilars
FDA hopes for major impact of Niazi proposals on biosimilar development
10 March 2026
Biosimilars
Sandoz creates new global biosimilar unit
10 March 2026
Pharmaceutical
Lundbeck appoints chief AI officer to drive strategy
10 March 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze